Cargando…
Evolution of Multiple Domains of the HIV-1 Envelope Glycoprotein during Coreceptor Switch with CCR5 Antagonist Therapy
HIV-1 uses CD4 as a receptor and chemokine receptors CCR5 and/or CXCR4 as coreceptors. CCR5 antagonists are a class of antiretrovirals used to inhibit viral entry. Phenotypic prediction algorithms such as Geno2Pheno are used to assess CCR5 antagonist eligibility, for which the V3 region is screened....
Autores principales: | Du, Yueqi, Wu, Ellen, Gao, Xiang, Zhang, Jie, Martin, John C., Rosa, Bruce A., Mitreva, Makedonka, Ratner, Lee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431240/ https://www.ncbi.nlm.nih.gov/pubmed/35727047 http://dx.doi.org/10.1128/spectrum.00725-22 |
Ejemplares similares
-
Evolution of coreceptor utilization to escape CCR5 antagonist therapy
por: Zhang, Jie, et al.
Publicado: (2016) -
The Variable Loop 3 in the Envelope Glycoprotein Is Critical for the Atypical Coreceptor Usage of an HIV-1 Strain
por: Xiang, Yue, et al.
Publicado: (2014) -
Endocytosis and Recycling of the HIV Coreceptor Ccr5
por: Signoret, Nathalie, et al.
Publicado: (2000) -
HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage
por: Santos-Costa, Quirina, et al.
Publicado: (2014) -
Structural basis of coreceptor recognition by HIV-1 envelope spike
por: Shaik, Md Munan, et al.
Publicado: (2018)